Litcius/Paper detail

Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin

Adam C. Palmer, David M. Kurtz, Ash A. Alizadeh

2023New England Journal of Medicine59 citationsDOI

Topics & Concepts

Computational biologyMedicineCancer researchInternal medicineOncologyBiologyMonoclonal and Polyclonal Antibodies ResearchCAR-T cell therapy researchHER2/EGFR in Cancer Research
Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin | Litcius